Milford Molecular Diagnostics

2044 Bridgeport Ave, Milford, CT 06460

 


Lyme Disease DNA Test


"DNA sequencing-based diagnostics are our specialty and routine diagnostic DNA sequencing is the gateway to practicing personalized molecular medicine."


Sin Hang Lee, MD, F.R.C.P.(C), FCAP



Loading

DNA Sequence Testing


DNA sequencing-based tests for Lyme disease and Lyme disease-like Borrelioses

DNA sequencing, namely the Sanger sequencing technology, is the commonly used “gold standard” for validation of the results of all other nucleic acid-based clinical tests. Ötzi the Iceman who died 5,300 years ago had Lyme disease which was diagnosed in 2012 by DNA sequencing of the genomic DNA remnants of Borrelia burgdorferi preserved in the cadaver. We are using the same approach to diagnose Lyme disease and Lyme disease-like borrelioses when the pathogens are still in the blood, in the joint fluid or in the cerebrospinal fluid of a patient. This technology is especially useful in testing for Borrelia miyamotoi infections because its “diagnosis currently relies on the use of tests to detect DNA of the organism”, as stated in a CDC guideline [3]. 


The principle of DNA sequencing-based tests for Lyme Borreliosis

We perform nested PCR amplification of a highly conserved segment of the 16S ribosomal RNA gene (16S rDNA) with hypervariable regions of the pathogenic borreliae isolated from the patient’s samples. All bacteria have 16S rDNA which is needed to initiate protein synthesis. Each bacterial species has its own unique 16S rDNA “signature sequence”. If the sample is positive for this unique segment of DNA, a Sanger sequencing of the PCR amplicon is performed for validation of the PCR products. The sequencing data are submitted to the GenBank for sequence alignment analysis. The GenBank report confirms the molecular diagnosis.

However, the bacteria causing Lyme borrelioses usually contain only one copy of this DNA segment per spirochete, and there are very few Lyme bacteria in the circulating blood even at the spirochetemic stage of the infection. For this reason, we have adopted a nested PCR technology to increase the PCR sensitivity, using a high-fidelity low temperature PCR system for DNA target amplification [4].  

The results of DNA sequencing versus the two-tier serology test results in diagnosing Borrelia burgdorferi and Borrelia miyamotoi infections during spirochetemia, are shown in the following two actual cases based on testing the patient’s split serum sample. The two-tier serology results were ambiguous. The DNA sequencing results were not. 

*Special Note: Serum is a very poor sample for routine detection of infectious agents. Most spirochetes are trapped in the blood clot.

Case 1:  Lyme disease with Borrelia burgdorferi

The patient presented with clinical symptoms of possible Lyme disease and a two-tier serology test reporting an ELISA value of 0.72, an IgM Western Blot positive for the 41 and 23 bands, and an IgG Western Blot positive for the 66 and 41 bands. Residual bacteria of Borrelia burgdorferi were found in the serum sample, and confirmed by PCR and DNA sequencing as follows.

Case 2:  Atypical “Lyme disease” with Borrelia miyamotoi 

The patient presented with clinical symptoms of possible Lyme disease and a two-tier serology test reporting an ELISA value of 0.65, a negative IgM Western Blot, and an IgG Western Blot positive for a 41 band. Residual bacteria of Borrelia miyamotoi were found in the serum sample, and confirmed by PCR and DNA sequencing as follows.


Case 3:  Diagnosis of Lyme
Borreliosis in Ticks

This technology is also useful to diagnose infections by Borrelia burgdorferi and Borrelia miyamotoi in ticks, based on a protocol previously reported [1]. A diagnostic DNA sequencing electropherogram of Borrelia miyamotoi 16S rDNA isolated from the archived carcass of a tick removed from the skin bite of a patient living in Connecticut is illustrated below.





References

[1] Lee SH, Vigliotti VS, Vigliotti JS, Jones W, Pappu S. Increased Sensitivity and Specificity of Borrelia burgdorferi 16S Ribosomal DNA Detection.  Am J Clin Path. 2010;133:569-576.

[2] Lee SH, Vigliotti VS, Vigliotti JS, Jones W, Williams J, Walshon J. Early Lyme disease with spirochetemia – diagnosed by DNA sequencing. BMC Res Notes. 2010;3:273.

[3] http://www.cdc.gov/ticks/miyamotoi.html

[4] Hong G, Lee SH, Ge S, Zhou S. A Novel Low Temperature PCR Assured High-Fidelity DNA Amplification. International Journal of Molecular Sciences. 2013; 14(6):12853-12862.

[5] Lee SH, Vigliotti VS, Vigliotti JS,  Pappu S. Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer 2007; 2:11. 

[6] Lee SH, Vigliotti VS, Pappu S. Human papillomavirus (HPV) infection among women in a representative rural and suburban population of the United States. Inter J Gyn Ob.  2009; 105:210-214.

[7] Lee SH, Pappu S. Validation of human papillomavirus genotyping by signature DNA sequence analysis. BMC Clin Pathol  2009; 9:3.

[8] Lee SH, Pappu S. Signature sequence validation of human papillomavirus type 16 (HPV-16) in clinical specimens. J Clin Path. 2010;63:235-239. 

[9] Lee SH: Chapter 5 in “Guidelines for the use of molecular tests for the detection and genotyping of human papilloma virus from clinical specimens.” Methods Mol Biol 2012; 903:65-101.

[10] Lee SH, Vigliotti VS, Pappu S. DNA Sequencing Validation of Chlamydia trachomatis and Neisseria gonorrhoeae Nucleic Acid Tests. Am J Clin Pathol. 2008;129:852-859. 

[11] Lee SH,  Vigliotti VS, Pappu S. Molecular tests for human papillomavirus (HPV), Chlamydia trachomatis and Neisseria gonorrhoeae in liquid-based cytology specimen.  BMC Women’s Health 2009; 9:8.